New Drug Could Reduce Death Risk for Women With Common Cancer
Summary
A phase 3 trial found that sacituzumab tirumotecan (sac-TMT) was associated with lower risks of cancer progression and death than standard chemotherapy in women with advanced or recurrent endometrial cancer. The trial also found longer median survival and more tumor responses among women who received the drug; further details on the study’s limits are not available in the provided article text.Key Facts
- The study enrolled 776 women with advanced or recurrent endometrial cancer who had previously received chemotherapy and immunotherapy.
- Researchers assigned 386 participants to sac-TMT and 390 to standard chemotherapy.
- The study reported a 41% lower risk of cancer progression and a 32% lower risk of death with sac-TMT compared with chemotherapy.
- Median survival was 19 months with sac-TMT and 12 months with chemotherapy, according to the study lead quoted in the article.
- Tumors shrank or otherwise showed a positive response in 35% of women receiving sac-TMT, compared with 17% receiving chemotherapy.
- The trial took place at more than 200 cancer centers in nearly 30 European countries.
- The results were published in The Lancet on October 26.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
